NMRD

Nemaura Medical Reports Fiscal Second Quarter 2023 Results and Provides Business Update

Retrieved on: 
Tuesday, November 15, 2022
Marketing, Regulation of tobacco by the U.S. Food and Drug Administration, Skin, Weight loss, NMRD, Food, Artificial intelligence, Annual report, Sumathi Best Television Current Reporting Award, PMA, Diabetes, Prediabetes, Kingdom, Calendar, CE, Research, FDA, CGM, Medical device, Risk management, Pharmaceutical industry, Nemaura Medical

Loughborough, England, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (Nemaura or the Company), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today releases its financial results for the quarter ending September 30, 2022 and provides a business update.

Key Points: 
  • Loughborough, England, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (Nemaura or the Company), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today releases its financial results for the quarter ending September 30, 2022 and provides a business update.
  • The launch is expected in the first calendar quarter of 2023 and will target insurers and corporate clients.
  • Our commercial and manufacturing scale-up activities accelerated in the fiscal second quarter, as we continue to scale operations to support commercialization of our non-invasive glucose monitoring devices and sensors said Nemaura CEO Dr. Faz Chowdhury.
  • Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.

Nemaura Receives Provisional Purchase Order from Middle East Licensee TPMENA

Retrieved on: 
Wednesday, October 12, 2022
U.S. Securities and Exchange Commission, MENA, Weight loss, PMA, Annual report, NASDAQ, Regulation of tobacco by the U.S. Food and Drug Administration, Research, Type 2, Translation, Type 2 diabetes, Artificial intelligence, Food, NMRD, CGM, Company, Marketing, Prediabetes, Diabetes, International Diabetes Federation, CE, Skin, GLOBE, Kingdom, FDA, Sumathi Best Television Current Reporting Award, Language, Pharmaceutical industry, Weapon, Medical device, KSA, Nemaura Medical

(NASDAQ: NMRD) (Nemaura or the Company), a medical technology company focused on developing and commercialising noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced it has received a provisional purchase order from TPMENA, its MENA (Middle East/North Africa) licensee for the Companys sugarBEAT system.

Key Points: 
  • (NASDAQ: NMRD) (Nemaura or the Company), a medical technology company focused on developing and commercialising noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced it has received a provisional purchase order from TPMENA, its MENA (Middle East/North Africa) licensee for the Companys sugarBEAT system.
  • TPMENA issued the provisional purchase order with Nemaura following its regulatory registration submission for sugarBEAT in the Kingdom of Saudi Arabia (KSA).
  • We believe the Middle East, and Saudi Arabia in particular, represents a significant opportunity for Nemaura and its partner TPMENA, given the high rates of Type II diabetes in the region, said Nemaura CEO, Dr. Faz Chowdhury.
  • Based in Dubai, TPMENA is a full-service distributor that markets premium international brands in the Middle East region and brings significant expertise in logistics, marketing, distribution, and sales.

Nemaura Medical to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference

Retrieved on: 
Tuesday, October 4, 2022
GLOBE, NASDAQ, CE, Nemaura Medical, CEO, Population, Prediabetes, CGM, Weight loss, Artificial intelligence, NMRD, Program, Conference, PMA, Diabetes, Company, Medical device

Loughborough, England, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at at the MicroCap Rodeo Windy City Roundup 2022 Conference.

Key Points: 
  • Loughborough, England, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at at the MicroCap Rodeo Windy City Roundup 2022 Conference.
  • The conference is being held on October 12 13, 2022 at the Swissotel Chicago.
  • Dr. Chowdhury will be available for one-on-one meetings with investors who are registered to attend the conference.
  • To schedule a meeting, please email [email protected]
    To register for the conference, click here: https://microcaprodeo.com/signup
    Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.

Wearable Medical Devices Revolutionize How Patient Data Can be Tracked

Retrieved on: 
Wednesday, September 28, 2022
Vital signs, Privacy, Safety, Algorithm, Diabetes, Financial News, Industry, Social media, Portsmouth Aerocar, USD, Patient, MDT, Technology, Yoga, NASDAQ, Sleep, Research, NMRD, Communication, Adoption, Blood pressure, Prevalence, Editorial, Glycated hemoglobin, Organization, Acquisition, Policy, Wearable, Type 2, Type 2 diabetes, MDI, CGM, MNI - Market News, Privacy policy, Non-invasive ventilation, CAGR, Human, NYSE, News, ADAPT, Mathematics, CPAP, Walking, Instagram, Goal, Heart rate, Contextual advertising, SENS, Marketing, Disclosure, The Lancet, Twitter, Weight loss, Advertising, MRI, Huawei, Bias, Google Images, Use, GRMN, Medical imaging, Pharmaceutical industry, Mobile phone, Public relations, Politics, Suunto, Nemaura Medical, Medtronic, Garmin

NEW YORK , Sept. 28, 2022 /PRNewswire/ -- Some of the fastest growing segments in the medical device market by application include diagnostic devices like patient-monitoring systems, MRI machines, diagnostic imaging equipment (including X-ray devices and other diagnostic imaging), and ultrasonic scanning devices. In recent times, remote patient-monitoring devices have become more popular due to the pandemic and social distancing measures which were implemented to combat it. Most commonly, these medical wearable devices are designed to collect data and measure vital signs such as heart rate, blood pressure, blood oxygen saturation, blood glucose levels and more. Herman Bonner, communication specialist at Firstbeat, which powers stress tracking features in a host of wearables from the likes of Garmin, Huawei and Suunto, explained in an article by Wareable that "it takes a lot of specialized expertise in mathematics, signal processing, pattern recognition, and programming to get to the point where you are providing useful information to people." Nemaura Medical Inc. (NASDAQ: NMRD), AdaptHealth Corp. (NASDAQ: AHCO), Senseonics Holdings, Inc. (NYSE: SENS), Medtronic plc (NYSE: MDT), Garmin Ltd. (NYSE: GRMN)

Key Points: 
  • In recent times, remote patient-monitoring devices have become more popular due to the pandemic and social distancing measures which were implemented to combat it.
  • Most commonly, these medical wearable devices are designed to collect data and measure vital signs such as heart rate, blood pressure, blood oxygen saturation, bloodglucose levels and more.
  • Nemaura Medical Inc. (NASDAQ: NMRD), AdaptHealth Corp. (NASDAQ: AHCO), Senseonics Holdings, Inc. (NYSE: SENS), Medtronic plc (NYSE: MDT), Garmin Ltd. (NYSE: GRMN)
    Wearable medical devices are now playing a larger role in the healthcare industry than ever before.
  • And, according to data published by Grand View Research, Inc., the global wearable medical devices market size was valued at USD 16.6 Billion in 2020.

Wearable Medical Devices Revolutionize How Patient Data Can be Tracked

Retrieved on: 
Wednesday, September 28, 2022
Vital signs, Privacy, Safety, Algorithm, Diabetes, Financial News, Industry, Social media, Portsmouth Aerocar, USD, Patient, MDT, Technology, Yoga, NASDAQ, Sleep, Research, NMRD, Communication, Adoption, Blood pressure, Prevalence, Editorial, Glycated hemoglobin, Organization, Acquisition, Policy, Wearable, Type 2, Type 2 diabetes, MDI, CGM, MNI - Market News, Privacy policy, Non-invasive ventilation, CAGR, Human, NYSE, News, ADAPT, Mathematics, CPAP, Walking, Instagram, Goal, Heart rate, Contextual advertising, SENS, Marketing, Disclosure, The Lancet, Twitter, Weight loss, Advertising, MRI, Huawei, Bias, Google Images, Use, GRMN, Medical imaging, Pharmaceutical industry, Mobile phone, Public relations, Politics, Suunto, Nemaura Medical, Medtronic, Garmin

NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Some of the fastest growing segments in the medical device market by application include diagnostic devices like patient-monitoring systems, MRI machines, diagnostic imaging equipment (including X-ray devices and other diagnostic imaging), and ultrasonic scanning devices. In recent times, remote patient-monitoring devices have become more popular due to the pandemic and social distancing measures which were implemented to combat it. Most commonly, these medical wearable devices are designed to collect data and measure vital signs such as heart rate, blood pressure, blood oxygen saturation, blood glucose levels and more. Herman Bonner, communication specialist at Firstbeat, which powers stress tracking features in a host of wearables from the likes of Garmin, Huawei and Suunto, explained in an article by Wareable that "it takes a lot of specialized expertise in mathematics, signal processing, pattern recognition, and programming to get to the point where you are providing useful information to people." Nemaura Medical Inc. (NASDAQ: NMRD), AdaptHealth Corp. (NASDAQ: AHCO), Senseonics Holdings, Inc. (NYSE: SENS), Medtronic plc (NYSE: MDT), Garmin Ltd. (NYSE: GRMN)

Key Points: 
  • In recent times, remote patient-monitoring devices have become more popular due to the pandemic and social distancing measures which were implemented to combat it.
  • Most commonly, these medical wearable devices are designed to collect data and measure vital signs such as heart rate, blood pressure, blood oxygen saturation, bloodglucose levels and more.
  • Nemaura Medical Inc. (NASDAQ: NMRD), AdaptHealth Corp. (NASDAQ: AHCO), Senseonics Holdings, Inc. (NYSE: SENS), Medtronic plc (NYSE: MDT), Garmin Ltd. (NYSE: GRMN)
    Wearable medical devices are now playing a larger role in the healthcare industry than ever before.
  • And, according to data published by Grand View Research, Inc., the global wearable medical devices market size was valued at USD 16.6 Billion in 2020.

Nemaura Medical to Present at the 24th Annual H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022
CEO, Nemaura Medical, Program, Artificial intelligence, NASDAQ, NMRD, GLOBE, CGM, Conference, Company, Weight loss, Population, PMA, Prediabetes, Diabetes, CE, Medical device

Loughborough, England, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference, which is being held on September 12 14, 2022.

Key Points: 
  • Loughborough, England, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference, which is being held on September 12 14, 2022.
  • ET to H.C. Wainwright registered attendees of the conference.
  • To request a meeting and to register for the conference, click below:
    Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.
  • Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

Nemaura Medical Reports Fiscal First Quarter 2023 Results and Provides Business Update

Retrieved on: 
Monday, August 15, 2022
FDA, U.S. Securities and Exchange Commission, GLOBE, Food, Population, Sumathi Best Television Current Reporting Award, NMRD, Research, Annual report, CE, Prediabetes, Marketing, CGM, Company, Program, Skin, Artificial intelligence, PMA, Diabetes, Nasdaq, Total, Weight loss, Regulation of tobacco by the U.S. Food and Drug Administration, Medical device, Nemaura Medical

Loughborough, England, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (Nemaura or the Company), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today releases its financial results for the quarter ending June 30, 2022 and provides a business update.

Key Points: 
  • Loughborough, England, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (Nemaura or the Company), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today releases its financial results for the quarter ending June 30, 2022 and provides a business update.
  • We are very pleased with the progress we are steadily making with our manufacturing and commercialization support activities.
  • Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.
  • Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast Featuring Dr. Faz Chowdhury, CEO of Nemaura Medical Inc.

Retrieved on: 
Monday, August 8, 2022
Interview, Drug Quality and Security Act, Chowdhury, Nemaura Medical, CEO, GLOBE, Securities Exchange Act of 1934, SEC, Prescription, NMRD, IBN, Knowledge, Blood, Prediabetes, CGM, Review, NASDAQ, Artificial intelligence, Roy Taylor (scientist), Â, Social media, News, Securities Act of 1933, PMA, Diabetes, Goal, Solution, Time, Podcast, Medical device, Pharmaceutical industry, Public relations

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries.

Key Points: 
  • The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries.
  • Bell2Bells latest podcast features Dr. Faz Chowdhury, Chairman and CEO of Nemaura Medical Inc. (NASDAQ: NMRD) , a medical technology company developing and commercializing affordable diagnostic and digital tools for chronic disease management.
  • Throughout the interview, Chowdhury provided an introduction to Nemaura Medical and discussed its business model.
  • If you look at the market, there are something like half a billion people around the world with diabetes.

Nemaura Medical Granted UK Trademark “Meta Score,” a Digital Biomarker Term for its Metabolic Health Program

Retrieved on: 
Thursday, July 21, 2022
Diabetes, NMRD, Skin, GLOBE, U.S. Securities and Exchange Commission, Food, Research, Artificial intelligence, Regulation of tobacco by the U.S. Food and Drug Administration, Marketing, CGM, PMA, CE, Prediabetes, FDA, Company, Nasdaq, Sumathi Best Television Current Reporting Award, Annual report, Program, Weight loss, Population, Pharmaceutical industry, Medical imaging, Medical device, Nemaura Medical

Meta Score will be the metric and digital biomarker the Company will use as part of its consumer programs.

Key Points: 
  • Meta Score will be the metric and digital biomarker the Company will use as part of its consumer programs.
  • This digital biomarker will derive output from Nemauras glucose sensor in combination with a number of behavioral inputs of users.
  • Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.
  • Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022

Retrieved on: 
Thursday, June 30, 2022
Insurance, Prediabetes, FDA, Artificial intelligence, Annual report, CEO, Research, Weight loss, NMRD, PMA, GLOBE, Marketing, Prescription, Population, Sumathi Best Television Current Reporting Award, Company, Advertising, U.S. Securities and Exchange Commission, Awareness, Â, Diabetes, Food, CE, Technology, CGM, Calendar, Heel, Nasdaq, Regulation of tobacco by the U.S. Food and Drug Administration, Type 2 diabetes, Skin, GDP, Physician, Program, Education, Medical device, Pharmaceutical industry, EU, Nemaura Medical

Loughborough, England, June 30, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (Nemaura or the Company), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the fiscal year ended March 31, 2022.

Key Points: 
  • Loughborough, England, June 30, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (Nemaura or the Company), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the fiscal year ended March 31, 2022.
  • Commenced shipments of sugarBEAT continuous glucose monitor (CGM) devices to its UK licensee, MySugarWatch Limited (MSWL), previously DB Ethitronix Limited.
  • The initial Duo-Pack presentation will be launched as the first of these medicines loses its patent protection in the UK in the calendar fourth quarter of 2022.
  • We expect additional purchase orders to support the UK launch, as well as the anticipated Duo-Pack launch later in calendar 2022.